A group of Pune-based scientists have developed a 'liquid biopsy' technology to detect early spread of cancer and claim it is the fastest in the world.
The 'OncoDiscover' technology has been approved by the Central Drugs Standard Control Organisation, the national regulatory body for pharmaceuticals and medical devices, they said.
"This technology is expected to revolutionise the early diagnosis and management of cancer patients in India," said Dr Jayant Khandare, Chief Scientific Officer of Actorius Innovations and Research, a Pune-based start-up.
"OncoDiscover is the first-of-its-kind to be licensed to manufacture for sale under the new Medical Device Guidelines, 2017, for early detection of metastasis in epithelial origin cancers," he said.
Actorius has indigenously developed the more specific, highly rapid and efficient cancer diagnostic technology in detecting the early spread of cancers, Khandare told PTI.
The start-up has been funded for high-risk innovations by the Biotechnology Industry Research Assistance Council, an industry support wing of the Department of Biotechnology, he said.
A team of scientists led by Khandare and Aravindan Vasudevan worked to crack the technological challenges in detecting circulating tumor cells (CTCs) from lung, breast, colorectal, head and neck cancers.
"CTCs are extremely low in numbers, as low as one CTC is accounted for in millions of other blood cells. Their isolation and enumeration in a patient's blood is like finding a needle in a haystack," Khandare said.
The new technology has been patented internationally and "clinically validated" via multiple clinical trials, he said. One such was undertaken by Dr Pankaj Chaturvedi, noted oncologist and deputy director at the Tata Memorial Hospital in Mumbai.
While a similar CTC detection test approved by the US FDA costs USD 1,000 and is unaffordable for most Indians, OncoDiscover comes at a fraction of that cost, he said.
The test is now available in Pune at the OncoDiscover Liquid Biopsy Technology lab for cancer patients in India, he added.
Khandare was in 2011 awarded the Alexander von Humboldt Experienced Researcher Fellowship for his research in macromolecular chemistry, involving work on targeting cancer cells and in inflammation using ligands and hyper-branched polymers.
The Germany-based Humboldt Foundation gives this award and 44 of the awardees have gone on to win the Nobel Prize.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
